GLP1 Medications UAE Availability & Cost 2026

Orforglipron UAE Price Snapshot

Foundayo is the UAE-listed brand name for orforglipron, Eli Lilly's once-daily oral non-peptide GLP-1 receptor agonist. The clearest UAE retail signal currently comes from myAster, which lists six 30-tablet Foundayo bottle strengths. These are pharmacy listing prices, not medical advice, and they can change by stock, location, delivery channel, or insurer decision.

Source note: myAster's Foundayo brand page lists a price filter range of AED 773-AED 1,599 and individual product pages identify Foundayo as prescription-only.^[myAster] Verify current availability and dispensing requirements directly with the pharmacy before relying on any quoted AED figure.

Scope Note for UAE Readers

This guide uses one table for two different categories: licensed prescription medicines and investigational research compounds. Ozempic, Wegovy, and Mounjaro are discussed as prescription products that require a licensed physician. Retatrutide is discussed only as an investigational compound for in-vitro laboratory research, with Remy-specific proof limited to batch documentation, COA verification, published pricing, and supply-route transparency.

When a price or availability detail changes, we update the visible date and keep the research-use disclaimers intact rather than turning the article into medical advice or a treatment recommendation.

These are indicative ranges that vary by pharmacy, clinic, dose, and date checked, not fixed prices. Mounjaro signals indicatively around AED 1,800-2,500/pen and Wegovy around AED 1,199-3,000/month, while Ozempic pricing varies widely by pharmacy and dose — UAE listings conflict enough that we do not pin it to a single figure here. Rybelsus and Saxenda sit at the lower end (AED ~800-1,100). Zepbound is Eli Lilly's US brand name for the weight-loss indication of tirzepatide; UAE pharmacies dispense the same molecule under the Mounjaro name. Orforglipron is EDE-approved (early April 2026) and now appears in myAster listings as Foundayo, with visible 30-tablet prices from AED 773 to AED 1,599 as of June 1, 2026. Every approved entry on the table requires a prescription from a DHA- or DOH-licensed physician. Prices vary; verify against current UAE pharmacy listings.

What Are the Prescription Requirements in the UAE?

All GLP-1 receptor agonist medications—including Ozempic, Mounjaro, Wegovy, Rybelsus, and Saxenda—are classified as prescription-only drugs in the UAE. A valid prescription from a DHA- or DOH-licensed physician is required before any pharmacy can dispense these medications. The Dubai Health Authority has issued specific guidance against self-medication with GLP-1 compounds.

GLP-1 prescriptions are available through major UAE pharmacy chains, including BinSina Pharmacy, Aster Pharmacy, and Life Pharmacy. Some pharmacies offer online ordering and delivery services, but a valid prescription must be presented or uploaded before dispensing.

Clinics offering GLP-1 consultation and prescription in the UAE include:

• Zone.Health — specialist GLP-1 weight management clinic in Dubai
• Euromed Clinic — medical weight loss programs with GLP-1 therapy
• Emirates Hospitals — endocrinology and metabolic health departments
• Endocare Clinic — dedicated endocrinology and diabetes center

Purchasing GLP-1 medications without a valid prescription is illegal under UAE pharmaceutical regulations. The DHA has issued public warnings against self-medication with weight loss injectables, citing risks of dosing errors, contraindication conflicts, and counterfeit products in unregulated channels. For a side-by-side tolerability comparison of these medications, see our Ozempic vs Mounjaro vs Wegovy side effects review.

Why Is There an Insurance Coverage Gap?

UAE medical insurance companies generally do not cover GLP-1 receptor agonist prescriptions when prescribed for weight loss or obesity management. This exclusion applies to Ozempic, Wegovy, Mounjaro, Saxenda, and Rybelsus when the primary indication is weight reduction rather than type 2 diabetes management.

When GLP-1 medications are prescribed specifically for type 2 diabetes, partial insurance coverage may be available depending on the individual policy and insurance provider. However, coverage for the diabetes indication varies significantly between insurers and plan tiers, and pre-authorization is typically required.

This coverage gap creates a substantial out-of-pocket cost of AED 744–1,734 per month for most patients seeking GLP-1 therapy for weight management. At current pricing, annual treatment costs range from approximately AED 8,900 to AED 20,800—a significant financial barrier for many residents. For detailed Wegovy pricing and dosing schedules in the UAE market, see our Wegovy price and dosing guide.

The international price gap is widening rather than narrowing. As of February 2026, US list pricing on Wegovy and Zepbound is moving toward AED 899–1,285 per month through Lilly Direct and NovoCare home-delivery programmes, while UAE retail pricing on the same molecules remains anchored above AED 1,000 with no reimbursement guarantee for the weight-management indication.^[GN] The result is a structural premium that UAE buyers pay for clinician-gated access, customs clearance, and cold-chain handling — not for the medication itself. Source: Gulf News, February 7, 2026.

Despite these costs, demand is surging. The UAE GLP-1 receptor agonist market is projected to reach USD 371.6 million by 2030, driven by rising obesity prevalence and growing awareness of these therapies. The gap between clinical demand and insurance coverage remains one of the defining dynamics of the UAE weight management landscape. Our Ozempic alternatives in Dubai article breaks down cost-per-receptor across available compounds.

On the supply side, Novo Nordisk and the Emirates Drug Establishment announced (May 22, 2026) the UAE as one of three global pharmaceutical distribution hubs worldwide, serving roughly 70 countries and 2.6 million patients. For UAE readers that is a structural supply-chain reassurance signal — local semaglutide and tirzepatide availability sits behind a major regional distribution base, even as price and reimbursement remain the binding constraints.

For a data-first read on the epidemiology behind that demand, see our UAE obesity statistics and GLP-1 landscape analysis. If the search shifts from UAE pharmacy access into wider country routing across Saudi Arabia, Qatar, or Lebanon, use the UAE, GCC and Lebanon guide hub.

What Does the UAE Obesity Landscape Look Like?

The UAE has one of the highest obesity rates globally, creating significant demand for effective pharmacological interventions. A 2025 cross-sectional study of over 440,000 adults in Dubai found that 63% of the adult population is overweight or obese, with 28% classified as obese by BMI criteria. For the full epidemiology behind this demand, see our UAE obesity statistics & GLP-1 landscape breakdown.

The diabetes burden is equally significant. The UAE has a 19.3% diabetes prevalence—among the highest rates worldwide—and this figure is projected to continue rising. UAE nationals have a higher prevalence of overweight and obesity (68.3%) compared to expatriate populations, reflecting both genetic predisposition and lifestyle factors in the region. GLP-1 usage is also growing among non-diabetic populations, a trend with its own body of clinical evidence.

These epidemiological realities have positioned the UAE as the fastest-growing GLP-1 market in the Middle East and Africa region. The convergence of high obesity prevalence, high disposable income, medical tourism infrastructure, and limited insurance coverage creates a unique market dynamic where out-of-pocket spending on GLP-1 therapies is substantial and growing.

Orforglipron in the UAE — Oral GLP-1 Approval Status

Orforglipron is Eli Lilly's oral, non-peptide GLP-1 receptor agonist — the first small-molecule entry to the class and the first credible needle-free alternative to weekly injections. Because it is taken by mouth rather than injected, it does not require refrigeration, which is a meaningful logistics shift for UAE distribution. The FDA approved orforglipron on April 1, 2026 under the brand name Foundayo, and the Emirates Drug Establishment (EDE) approved it for the UAE in early April 2026. As of this June 1, 2026 check, myAster UAE lists six Foundayo 30-tablet strengths from AED 773 to AED 1,599.

Orforglipron UAE price: AED 773-1,599 in current pharmacy listings

Current UAE retail visibility starts with myAster's Foundayo listings: AED 773 for 0.8mg and 2.5mg, AED 1,115 for 5.5mg, AED 1,412 for 9mg, and AED 1,599 for 14.5mg and 17.2mg 30-tablet bottles. These are listed pharmacy prices, not a guarantee of current stock or insurance coverage. EDE reference pricing still matters because the federal framework benchmarks against reference markets and applies agent and pharmacy margin limits. Insurance treatment will likely mirror the existing GLP-1 pattern: covered more often for diabetes indications, generally excluded for weight management.

For the regulatory timeline, see is orforglipron approved. For Eli Lilly’s commercial brand framing, see Foundayo (orforglipron) FDA approval status.

Foundayo (Orforglipron) — Eligibility, Trial Efficacy & Side Effect Profile

Foundayo is the US brand name for orforglipron, the first non-peptide oral GLP-1 receptor agonist approved for chronic weight management. Because it is a small molecule rather than a peptide, it is taken as a daily tablet without strict food, water, or timing restrictions — a meaningful adherence shift compared with weekly injectable GLP-1s. For UAE residents, the practical question is no longer “is it approved” but “who is eligible, what is the published efficacy, and what are the side effects on the FDA label.”

Eligibility on the Foundayo label

The Foundayo label aligns with the broader GLP-1 obesity-class pattern. It is indicated for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. UAE prescribing decisions sit with DHA- or DOH-licensed physicians; this article is reference, not advice. For the comparative landscape including next-generation injectable agents, see retatrutide vs orforglipron.

Published trial efficacy — ATTAIN-1 / ATTAIN-2

Eli Lilly’s ATTAIN Phase 3 program is the basis for the Foundayo approval. In ATTAIN-1 (adults with obesity, no type 2 diabetes), participants on the highest orforglipron dose lost roughly 12 kg over 72 weeks — placing oral orforglipron between Saxenda and Wegovy on weight-loss efficacy and well below tirzepatide and retatrutide. ATTAIN-2 (adults with type 2 diabetes) showed HbA1c and weight reductions consistent with the broader oral GLP-1 class. For a head-to-head against the semaglutide pen, see our orforglipron vs Wegovy pill comparison.

Common side effects on the Foundayo label

The Foundayo label lists the canonical GLP-1-class adverse-event profile, dominated by gastrointestinal symptoms during titration:

• Nausea
• Constipation
• Diarrhea
• Vomiting
• Indigestion
• Abdominal pain
• Headache
• Fatigue

These effects are typically dose-dependent and concentrated in the early titration window, mirroring the pattern observed with injectable semaglutide and tirzepatide. For a side-by-side tolerability read, see the Ozempic vs Mounjaro vs Wegovy side effects review.

Serious adverse events flagged on the label

The Foundayo label also flags the GLP-1-class serious adverse events, several of which require clinician evaluation rather than self-management:

• Pancreatitis: persistent severe abdominal pain, often radiating to the back, requires immediate medical evaluation.
• Severe gastrointestinal disease: intractable nausea, vomiting, or signs of obstruction.
• Dehydration leading to acute kidney injury: volume loss from severe GI symptoms can stress kidney function; baseline labs help frame this risk — see the blood tests before GLP-1s checklist.
• Serious allergic reactions: anaphylaxis or angioedema.
• Thyroid C-cell tumors: the GLP-1 class boxed warning carries forward to Foundayo, with personal or family history of medullary thyroid carcinoma or MEN2 listed as a contraindication. Symptoms warranting clinician review include a neck lump or swelling, hoarseness, trouble swallowing, or shortness of breath.

UAE regulatory context

The Emirates Drug Establishment (EDE) is the federal authority responsible for reviewing safety, efficacy, and clinical-trial data for new medicines. The EDE's role — led by Dr. Fatima Al Kaabi as Director-General — is to align UAE access with international approvals while applying federal reference-pricing rules. For Foundayo, EDE approval was granted in early April 2026, following the FDA decision; the next milestones are wider pharmacy stock visibility, any EDE reference-price publication, and individual insurer decisions about coverage on the diabetes versus weight-management indication.

How GLP-1 Weight Loss Injections Work

Mechanism

GLP-1 receptor agonists mimic the gut hormone glucagon-like peptide-1. They slow gastric emptying, blunt post-meal glucose spikes, and signal satiety in the hypothalamus—so calorie intake drops without willpower doing the heavy lifting. Subcutaneous dosing keeps blood levels steady, which is why weekly weight loss injections like Ozempic and Mounjaro outperform older oral options on adherence and effect size. For receptor-level pathway context across GLP-1, GIP, and glucagon, see the GLP-1 / GIP / glucagon mechanism of action review. Before a clinician starts therapy, baseline markers such as HbA1c, CMP, lipids, and kidney function help frame risk; see the blood tests before GLP-1s checklist. For dosing, titration, and trial data on the GIP/GLP-1 dual agonist, see our Mounjaro (tirzepatide) injection guide.

Trial-Average Weight Loss

Ozempic: 10–15% over 68 weeks at 2.0mg. Wegovy: 14.9% in STEP 1 at 2.4mg. Mounjaro: 20–25% across the SURMOUNT series. Saxenda: ~6% over 56 weeks at 3mg. For a side-by-side, see the weight loss injections comparison guide.

Dosing & Eligibility in the UAE

Starting Doses & Titration

All weekly GLP-1s start low and step up to limit GI side effects. Ozempic begins at 0.25mg/week for four weeks, then 0.5mg, with maintenance at 1.0–2.0mg depending on response. Wegovy follows a 5-step titration over 16 weeks to a 2.4mg maintenance dose. Mounjaro starts at 2.5mg/week and titrates to 5–15mg.

Eligibility Thresholds

Trial-aligned eligibility is BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia, OSA). UAE prescribing decisions are made by a DHA- or DOH-licensed physician—this article is reference, not advice.

Blood Sugar & Metabolic Effects

Blood Sugar & Insulin Sensitivity

Glucose improvements typically appear within the first 4–8 weeks—before substantial weight loss. In type 2 diabetes trials, Ozempic and Mounjaro both produce HbA1c reductions of 1.0–1.8%, putting them among the most effective glucose-lowering agents on the UAE market.

Lipids, Liver, Blood Pressure

Beyond glucose, GLP-1 trials report lower LDL, reduced liver fat, and modest blood-pressure drops. These effects often track ahead of what weight loss alone would predict, suggesting direct receptor-driven mechanisms—a useful detail for protocol design in metabolic research.

Emerging research signals (2026)

Two 2026 publications added research-only context to the GLP-1 literature; both are reported here as scientific findings, not as treatment or dosing guidance. A prespecified analysis of the SELECT trial (Nature Medicine, April 2, 2026) looked at participants with a FIB-4 ≥1.3 (a marker suggesting liver fibrosis): over 104 weeks, semaglutide lowered the fatty liver index roughly 28% more than placebo (HR 0.72; P<0.0001) and reduced cardiovascular events in this higher-fibrosis subgroup. Separately, the first peer-reviewed RCT of a GLP-1 receptor agonist in treatment-seeking alcohol use disorder with comorbid obesity (The Lancet, May 2, 2026; n=108, 26 weeks) found semaglutide cut heavy-drinking days 13.7 percentage points more than placebo (95% CI −22.0 to −5.4; p=0.0015). These are early research signals in the published GLP-1 evidence base; they are not claims about any Remy Peptides research compound.

Side Effects in the Titration Window

Common GI Effects

Nausea, vomiting, diarrhoea, and constipation are the dominant adverse events. They’re dose-dependent and concentrate in the first month after each step-up. Trial data: roughly 30–50% of patients report at least one GI symptom in month one, with incidence falling sharply by month three. For a social-signal view of how this titration window appears in public discussion, see the GLP-1 side-effects online communities analysis.

If Symptoms Persist

Persistent symptoms usually resolve with a slower titration, a temporary dose hold, or switching molecule. UAE prescribers manage this directly; the data above is published trial behaviour, not a prescribing recommendation.

What the Trials Pair the Drug With

Every Phase 3 weight-loss trial pairs the drug with a reduced-calorie diet and ~150 minutes/week of physical activity. That pairing is part of the published efficacy number, not a separate add-on—when researchers reference “14.9% on Wegovy” or “22.5% on Mounjaro”, that’s the combined intervention, not the drug in isolation. The data above is published trial behaviour; UAE prescribing decisions sit with DHA- or DOH-licensed clinicians.

UAE Treatments Beyond GLP-1

IV Drips, Gastric Balloons, Other Devices

Dubai wellness clinics market IV drips (lipotropic, B-complex, amino acids), gastric balloons, cryolipolysis, and meal-replacement programmes alongside the injectables. Evidence quality varies—most trial-grade weight-loss data still sits with the GLP-1 class, the dual GIP/GLP-1 class, and the new triple agonists.

Research-Grade Retatrutide

For laboratory use in the UAE, Remy Peptides supplies HPLC-verified retatrutide UAE formats for in-vitro research peptides UAE programmes, with batch documentation in our Janoshik COA library. Comparison reads: Retatrutide vs Orforglipron for the triple-agonist vs oral GLP-1 contrast, and Retatrutide vs Tirzepatide vs CagriSema for the multi-receptor comparison.

Clinical Trials & the Future of GLP-1s in the UAE

The 2026 GLP-1 pipeline is the most active phase of obesity drug development on record. Three programmes shape the near-term picture for UAE researchers and prescribers, and each is moving on its own readout cadence.

Orforglipron beyond Foundayo

With Foundayo now FDA- and EDE-approved, the next-stage questions for orforglipron are real-world adherence, head-to-head positioning against injectable semaglutide and tirzepatide, and longer-term durability beyond the 72-week ATTAIN endpoints. UAE access now hinges on dose-level pharmacy stock, any EDE reference-price publication, and individual insurer decisions about the obesity indication. For brand and pricing context, see Foundayo (orforglipron) FDA approval status.

Retatrutide — triple agonist (Phase 3)

Retatrutide is Eli Lilly’s GLP-1 / GIP / glucagon triple agonist. Phase 2 reported ~24.2% weight loss at 48 weeks at the top dose, and the Phase 3 TRIUMPH programme is ongoing. Retatrutide remains investigational and is not approved for human use anywhere; in the UAE it exists only as in-vitro research material with batch documentation. See retatrutide vs tirzepatide vs CagriSema for the multi-agonist comparison and the TRIUMPH titration guide for the published dosing schedule.

Survodutide — dual GLP-1/glucagon (Phase 3)

Survodutide is Boehringer Ingelheim and Zealand Pharma’s dual GLP-1/glucagon agonist, in Phase 3 obesity and MASH (NASH) programmes. It targets a different two-receptor combination than tirzepatide and could become a meaningful alternative if Phase 3 data hold. For status, see is survodutide approved.

What this means for UAE access

For UAE residents, the practical 12-month outlook is: Foundayo now joins Ozempic, Mounjaro, Wegovy, Rybelsus, and Saxenda on the approved-prescription side where pharmacy stock is available; retatrutide and survodutide remain investigational and (in retatrutide's case) accessible only as research material; and EDE-published reference prices, not launch headlines, will shape what UAE pharmacies actually charge over time.

What Is Available, and What Is Not Available Yet in the UAE?

Several entries in the GLP-1 cluster are now listed in UAE pharmacy channels, while others still should not be promised by any pharmacy or clinic. Mapping what is and is not legally dispensable removes the most common sources of confusion in this category.

Orforglipron UAE availability

Eli Lilly's oral, non-peptide GLP-1 was FDA-approved on April 1, 2026 as Foundayo and EDE-approved for the UAE in early April 2026. As of June 1, 2026, myAster lists Foundayo 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, and 17.2mg 30-tablet bottles, all marked prescription-only. See is orforglipron approved for the full status.

Foundayo

Foundayo is Eli Lilly's brand name for orforglipron, FDA-approved on April 1, 2026. The Emirates Drug Establishment approved orforglipron for the UAE in early April 2026, and UAE retail listings are now visible through myAster. Background: Foundayo / orforglipron FDA approval status.

Zepbound naming

Zepbound is Eli Lilly’s US brand for tirzepatide on the weight-loss indication. It is not a separate UAE pharmacy listing in the sources checked for this page. UAE tirzepatide access is routed under the Mounjaro name, regardless of whether the prescription is written for diabetes or weight management.

Retatrutide

Eli Lilly’s GLP-1/GIP/GCGR triple agonist remains investigational and is not approved by FDA, EMA, or MoHAP for human use anywhere. In the UAE it exists only as in-vitro research material with batch documentation; it is not a prescription product and cannot be dispensed by any pharmacy. See the scope note above for how this article handles approved versus research-use entries.

GLP-1 medications UAE — owner articles

For the dedicated per-drug references in this cluster, see Mounjaro Dubai price, Ozempic Dubai access, Wegovy price UAE, Rybelsus tablets UAE, and Weight loss injections Dubai.